	US RE50,320 E1
	APOE mimetic peptides and higher potency to clear plasma cholesterol
Gattadahalli M. Anantharamaiah, Birmingham, AL (US); and Dennis Goldberg, Sudbury, MA (US)
Assigned to UAB RESEARCH FOUNDATION, Birmingham, AL (US); and ANJI Pharmaceuticals INC., Cambridge, MA (US)
Appl. No. 17/748,682
Filed by UAB Research Foundation, Birmingham, AL (US); and ANJI PHARMACEUTICALS INC., Cambridge, MA (US)
PCT Filed Jul. 20, 2015, PCT No. PCT/US2015/041162 § 371(c)(1), (2) Date Jan. 27, 2017, PCT Pub. No. WO2016/018665, PCT Pub. Date Feb. 4, 2016.
Application 17/748,682 is a reissue of application No. 15/329,735, filed on Jul. 20, 2015, granted, now 10,653,747, issued on May 19, 2020.
Claims priority of provisional application 62/031,585, filed on Jul. 31, 2014.
Int. Cl. A61K 38/17 (2006.01); A61K 38/00 (2006.01); A61P 3/06 (2006.01); A61P 9/10 (2006.01); C07K 14/775 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 38/00 (2013.01); A61P 3/06 (2018.01); A61P 9/10 (2018.01); C07K 14/775 (2013.01)]

18 Claims

1. A synthetic apolipoprotein E(ApoE)-mimicking peptide comprising a receptor binding domain of ApoE and a lipid-associating peptide, wherein the synthetic ApoE-mimicking peptide comprises a fatty acid moiety, a ω-amino fatty acid moiety, or an acetylated ω-amino fatty acid moiety, wherein the lipid-associating peptide comprises a class A amphipathic helical domain, wherein the fatty acid moiety is a saturated fatty acid moiety, wherein the receptor binding domain of ApoE is on the N-terminus of the synthetic ApoE-mimicking peptide, and wherein the saturated fatty acid moiety [ , ω-amino fatty acid moiety, or acetylated ω-amino fatty acid moiety ] is at the N-terminus of the receptor binding domain of ApoE.